insulin glargine
Sanofi’s Toujeo proves non-inferior to insulin degludec in type 2 diabetes
June 26, 2018Manufacturing and Production, Research and Development, Sales and Marketing American Diabetes Association, Sanofi, diabetes, insulin glargine, pharma, toujeo, type 2 diabetes
Sanofi took the opportunity at the American Diabetes Association (ADA) 78th Scientific Sessions in Florida to unveil new data on …
Sanofi’s LixiLan meets target in Phase III diabetes trial
September 16, 2015Research and Development Lantus, LixiLan, Lixisenatide, Lxyumia, Sanofi, diabetes, insulin glargine, metformin, type 2 diabetes
Sanofi’s Phase III clinical trial of its Lixilan treatment has achieved its primary endpoint in patients with type 2 diabetes, …
Mixed Phase 3 results for Sanofi and UCB
July 29, 2015Research and Development LixiLan, Sanofi, UCB, clinical trials, epratuzumab, insulin, insulin glargine, phase III
Two drugs that pharma companies are pinning hopes on for future success have had mixed outcomes in key late-stage clinical …
Sanofi sees FDA approval for diabetes drug
February 26, 2015Sales and Marketing Afrezza, FDA, Q2, Sanofi, Twitter, diabetes, insulin glargine, q4
US regulators have approved Sanofi’s diabetes treatment Toujeo which is said to be a follow-up to the French firms key …
Sanofi sales lifted by diabetes and rare diseases
February 6, 2015Sales and Marketing Genzyme, Lantus, Sanofi, diabetes, financials, insulin glargine, praluent, q4
Sanofi racked up €7.4 billion in sales in the fourth quarter of 2014 according to the company’s latest financials report. …
Latest content
NIHR chief scientific adviser visits Huddersfield health innovation campus
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
